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Overall the D2cc values for the OAR have a lower percentage 
difference between planners than the D0.1cc due to the increased 
influence within the small volume. 
Conclusions: T2 MR imaging alone for reconstruction, using the 
external applicator surface, is reproducible between different 
planners. Slice thickness and inter-space gap are known parameters 
that can lead to uncertainties in applicator reconstruction, but by 
using mutual information from orthogonal sequences these 
uncertainties can be minimised. 
The changes in DVH parameters between planners are small, for both 
HR-CTV and all OARs, and would not result in a clinically significant 
change in terms of optimisation approach for the treatment plan. 
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Purpose/Objective: For brachytherapy of cervical cancers, the 
imaging modality of choice for delineation of targets and organ at 
risks (OAR) is T2-weighted MR imaging. Applicator reconstruction using 
MR imaging can be problematic for applicators composed of titanium. 
Titanium generates susceptibility artefacts on MR scans, causing signal 
voids near the titanium that may hamper applicator reconstruction. 
The goal of this study is to propose a novel MR sequence that yields 
non-deformed, high resolution and high contrast images that can be 
used for accurate and reproducible reconstruction of titanium 
applicators. The method is tested using a new design of the tandem 
and ovoid titanium Rotterdam applicator (Nucletron). 
Materials and Methods: A 1.5 Tesla MR scanner was used with a 3D 
radiofrequency Spoiled Gradient Recalled Echo sequence (SPGR, TE: 
1.1 ms, TR: 2.5, voxel size: 1.4x1.4x1.6 mm3, flip angle: 3o, number of 
excitations: 3) for imaging and applicator reconstruction. The 
geometrical accuracy of the applicator in the images was assessed 
using an in house developed gel filled phantom that could fixate the 
applicator. The inter-observer variability of applicator reconstruction 
was studied by analysing the results of eight different technicians that 
each performed applicator reconstruction for four different patients. 
The rigidity of the applicator allowed the use of a single library 
applicator, a digital model of the applicator with fixed dimensions, for 
applicator reconstruction. 
Results: On a standard T2 weighted scan, the titanium did not 
produce artefacts that hampered tumour delineation, but the contrast 
between the applicator and uterus was not sufficient for accurate 
applicator reconstructions. The 3D SPGR scan sequence yielded an 
excellent contrast between the soft tissues and the applicator, which 
was clearly visible as a signal void. When the intra-uterine was aligned 
with the B0 field,the width (FWHM) of its signal void was exactly 
equal to the real diameter of 3.0 mm, but it increased to 6.2 mm 
when the intra-uterine was tilted 46ocompared to the B0 field. 
Because the intra-uterine tube was located in the centre of the signal 
void (within 0.7 mm), the accuracy of applicator reconstruction was 
not affected by the expansion of the signal void for large tilt 
angles.This was confirmed by the excellent inter-observer variability 
among the eight technicians. The mean deviation for all reconstructed 
dwell positions was smaller than 1.0 mm and the maximum deviation 
of any dwell position among all patients and technicians was only 1.7 
mm. 
Conclusions: The titanium applicator was clearly visible on the 3D 
SPGR MR images, allowing applicator reconstruction with excellent 
accuracy and reproducibility. When used in addition to the standard 
T2 weighted MR images for tumour and OAR delineation, high 
accuracy MR guided brachytherapy is feasible with a titanium 
applicator. 
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Purpose/Objective: To compare the uncertainties of CT and MRI-T1 
based seed reconstruction in post-implant evaluation of permanent 
prostate brachytherapy in terms of interobserver variability, and to 
quantify the impact of this seed detection variability on a selection of 
dosimetric parameters for three postplan techniques: 1) CT only, 2) 
MRI-T1 fused with MRI-T2, and 3) CT fused with MRI-T2. 
Materials and Methods: Seven physicists reconstructed the seed 
positions on post-implant CT and MRI-T1 weighted images of three 
patients treated with I-125 seed brachytherapy. A reference seed set 
was defined by two experienced physicists. The reconstructed seeds 
were assigned to the reference seeds within an acceptance diameter 
of 15mm, using a dedicated Matlab program. For each patient and 
imaging modality the interobserver variability was calculated with 
respect to the reference (1 SDref). The effect of this variability on 
dosimetry (D90, V100, V150) was calculated for CT and for CT + MRI-T2 
(both techniques using CT based seed reconstruction), as well as for 
MRI-T1 + MRI-T2 (using MRI-T1 based seed reconstruction), for a fixed 
CT and MRI-T2 prostate contour. Contouring was done by two 
experienced uro-radiologists based on the post-implant CTV-P(rostate) 
definition according to the ESTRO/EAU/EORTC prostate recom-
mendations. 
Results: For CT, on average 98 % of the reconstructed seeds could be 
assigned to a reference seed, while the mean seed assignment rate for 
T1 was 93 %. Averaged over three patients, the interobserver 
variability in CT based seed reconstruction was 1.1 mm (1 SDref). This 
resulted in D90 variabilities < 2% (1 SDref) for CT and CT + MRI-T2, 
which is clinically acceptable (see table). Also the interobserver 
variabilities in V100 and V150 were small, with patient mean SDref values 
< 1% and < 4% respectively.  
The mean interobserver variability in MRI based seed reconstruction 
was 3.0 mm (1 SDref). This would be even larger if non-assigned seeds 
(outside the acceptance diameter) would be taken into account. The 
larger seed detection uncertainties on MRI-T1 compared to CT are due 
to the lack of an automated seed finder tool, and the fact that seeds 
are less clearly depicted on MRI. The impact of the interobserver 
variability on D90 was 6.6% for MRI-T1 + MRI-T2. 
Conclusions: Seed reconstruction on MRI-T1-weighted images was less 
accurate than on CT. This difference in uncertainties should be taken 
into account and weighted against uncertainties due to contouring and 
image fusion when comparing the overall reliability of postplan 
techniques. 
Table: Interobserver variability in seed reconstruction (averaged over 
three patients), expressed as (a) positional deviation (mm) and (b) 
dosimetric impact (%) with respect to the reference values. 
 
SDref in seed reconstruction (mm) CT MR-T1 
 1.1 mm 3.0 mm SDref in dosimetry (%) CT CT + MR-T2MR-T1 + MR-T2 
D90 
V100 
V150 
1.5 
0.9 
3.6 
1.3 
0.5 
3.2 
6.6 
2.8 
8.1 
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Purpose/Objective: The current clinical low dose rate (LDR) 
brachytherapy dosimetry protocol for low energy photons, AAPM 
TG43, ignores the effects of tissue composition. Given the 
photoelectric effect's dominance at the low photon energies, the 
dosimetry is dependent on the elemental composition and density of 
tissues. AAPM TG186 recently recommended that brachytherapy dose 
calculations take heterogeneities into account by using CT images. In 
LDR seed implants, metal streaking artefacts degrade density (ρ) 
information and limit the applicability of heterogeneity corrections. 
Metal artefact reduction (MAR) techniques have been presented, but 
are currently not clinically implemented in radiotherapy, possibly due 
to their complexity. Dual energy CT (DECT) imaging allows the 
reconstruction of mono energetic attenuation maps over a range of 
diagnostic energies. It has recently been shown that by carefully 
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choosing this mono-energy, it is possible to achieve MAR in patients 
with hip prostheses. This approach is simple and easy to 
implement.The goal of this study is to assess the MAR capacity of 
DECT in the context of LDR seed implants. More specifically, we aim 
to ascertain whether the use of DECT can yield dose calculations 
whose accuracy is not marred by metal artefacts. 
Materials and Methods: DECT imaging at 100 kVp and 140 kVp was 
performed on an ultrasound phantom designed for prostate implants 
containing inert LDR brachytherapy seeds. The magnitude of artefacts 
was evaluated as a function of mono-energetic attenuation maps by 
comparing the standard deviation (σ) in a region of interest (ROI) 
containing artefacts and one free of artefacts. The ROIs exclude the 
high signal from the seeds themselves. Additionally, the same analysis 
was performed on the density map obtained from the standard DECT 
ρ-Z decomposition which provides a density map directly. 
Results: 
 Figure 1 
Figure 1A shows the 140 kVp HU (displayed range=[-100 to 200 HU]) 
with streaking artefacts. Figure 1B shows the density map from ρ-Z 
decomposition (displayed range=[0.9 to 1.2 g/cc]). Comparing the 
140kVp HU image and the density map confirms that DECT provides 
MAR for seed implants. The magnitude of the metal artefacts in mono 
energetic images was found to decrease with increasing keV from 70 
keV to 150 keV, as can be seen in figure 1C. The ratio of σartefact/σno-
artefact(E) is plotted for the ROIs seen in Figure 1A. The σartefact/σno-
artefact(E) from the density map is plotted as a horizontal line. Our 
results suggest that the MAR from the density map from ρ-Z 
decomposition is better than the mono-energetic images, or 
alternately that the density map corresponds to the best high keV 
mono-energetic image. The increased noise in the density map can be 
reduced by optimizing the separation of the high and low kVp spectra. 
Conclusions: Mono-energetic images from DECT with a high keV 
provide MAR in seed implants. The MAR is equivalent to that obtained 
from the density map. The technique is promising and the impact on 
dose calculation accuracy will be investigated using Monte Carlo 
techniques. 
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Purpose/Objective: Brachytherapy provides one of the best cure rates 
for the treatment of prostate cancer but is highly skill dependent. An 
interactive electromagnetic needle navigation system was developed 
to reduce uncertainty in the implant procedure and expand the 
capabilities of patient-specific implant techniques. 
Materials and Methods: A gelatin phantom was placed inside the work 
space of a magnet field generator device which tracks the 3D 
locations of small EM-signal-producing coils. These coils were placed 
on the end of an endorectal ultrasound probe, upon the probe 
stepper, and embedded within the wall of a 16 gauge brachytherapy 
needle. The needle allows passage of a standard prostate 
brachytherapy seed. These coils provide real-time patient, probe, and 
needle coordinates. Additionally,the system has a mechanism by 
which the 3D coordinate and time information provided by the EM 
tracking device at the moment the seed is deposited in tissue can be 
automatically recorded. 
Experiments were performed to qualitatively determine the usability 
of the navigation system, as well as to measure the accuracy of the 
automated seed localization. Multiple seed implants were performed 
upon a phantom and the automated EM coordinates were compared to 
the‘true’ locations, as determined by a CT scan. These two coordinate 
systems were co-registered using a CT marker placed on the side of 
the phantom, for which the location was determined using the EM 
tracked needle by placing the tip upon opposite sides of the marker 
and averaging the locations’ coordinates. The precision of the seed 
localization is determined by evaluating the differences in relative 
seed locations within each coordinate system.  
Results: The system hardware, interface, and workflow validation 
experiments were implemented to demonstrate that EM needle 
tracking can guide implantation of seeds with minimal user expertise. 
Trials with the EM system have shown,qualitatively, an increase in 
usability and ease of needle navigation. Preliminary results also 
indicate the EM tracking seed localization is precise to 2.7 mm (1 
sigma). 
Conclusions: A system has been developed to assist the placement of 
radioactive seeds for the treatment of prostate cancer and reduce the 
dependence on physician skill-level, as well as facilitate skew-line 
needle arrangements and allow for improved mid-procedure re-
optimization based on seed deposition errors. The system will help 
reduce the number of attempts to bring a needle to the correct seed 
dropping location as well as facilitate the use of alternative needle 
pattern for organ sparing. Additionally, automated seed dropping 
detection will allow the system and user to know immediately the 
seed location and thereby adjust accordingly. Clinical implementation 
will be needed to determine the extent of increased precision and 
reduced trauma. 
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Purpose/Objective: We have previously shown that a flat panel 
imager can be used for source position localisation in HDR 
brachytherapy. Analysis of the EPID image distribution can be used to 
determine the source position relative to the EPID, but needed to be 
validated independently. Here we describe a method for the 
independent validation of source position coordinates determined in 
the two orthogonal directions parallel to the imager, using a novel 
projection technique combined with HDR source radiation subtraction. 
Materials and Methods: An a-Si EPID (IAS11-19, Varian Medical 
Systems, Palo Alto, CA, USA), removed from a linear accelerator, was 
positioned in contact with a rectangular solid water phantom, which 
included a ball-bearing array, placed against the surface of the 
imager. Brachytherapy catheters were inserted into grooves cut into a 
phantom slab at a distance of 50 mm from the imager surface. A 
mobile x-ray unit was set up at a relatively large distance (1500 mm) 
from the imager. Radio-opaque x-ray source position markers were 
inserted into the catheters and a projection image acquired using the 
external x-ray source and the EPID. A marker was removed and the 
Ir192 brachytherapy source was driven to 5 programmed dwell 
positions, at 10 mm steps, corresponding to the expected x-ray 
marker positions. At each dwell position two images were acquired: 
the first capturing only the radiation emitted by the Ir192 source, 
while the second image acquired also contained an exposure from the 
external x-ray system. Using image subtraction, the position of the 
projection of the physical Ir192 source could be determined and 
correlated with the marker projections (See Figure 1). To account for 
beam divergence effects, the distance of each projection from the 
central axis (CAX) of the external x-ray beam was determined. A 
stereotactic angiographic localisation frame was used as a set of 
known orthogonal pairs of radio-opaque markers, with the CAX 
determined by co-location of the perpendicular pair in the image.  
Results: The centroid coordinates of marker and source projections 
were derived and used to calculate object locations via geometric 
back-projection. Marker locations and the HDR source itself, identified 
using the subtraction method described here, were determined to 
within ± 0.4 mm (± half of the pixel size) at each programmed dwell 
position. Derived source positions matched the marker positions. 
 
